Integrated Molecular Tumor Board (iMTB) for reporting molecular data in precision cancer medicine

Acronym

iMTB-PCMed

Description of the granted funding

This proposal aims to develop a system for the prospective real-time reporting of clinically meaningful molecular findings, extracted from cancer patients' research profiling data using the integrative molecular tumor board (iMTB) tool and returned to the clinics via biobank. The iMTB tool and process development takes advantage of the data in iCAN Digital Precision Cancer Medicine Flagship project (www.ican.fi), where each patient's longitudinal health information is combined with molecular profiling data in a secure analysis platform. This project develops iMTB modules for omics and cohort analysis as well as focuses on automation and secure data return of the reports. In addition, we aim to integrate iMTB into hospital electronic health record system to systematically discover and utilize biomarkers of diagnostic, prognostic and therapeutic significance for the benefit of cancer patients.
Show more

Starting year

2026

End year

2028

Granted funding

Outi Monni
339 794 €



Contact person

Outi Monni

Role in consortium of the Academy of Finland

Leader

Other consortium parties

Partner
University of Helsinki (373151)
340 026 €
Partner
120 180 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Decision maker

Suomen akatemian muu päättäjä
05.12.2025

Other information

Funding decision number

373150

Fields of science

Genetics, developmental biology, physiology

Research fields

Perinnöllisyystiede

Identified topics

cancer